651 related articles for article (PubMed ID: 26948856)
1. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
[TBL] [Abstract][Full Text] [Related]
2. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
[TBL] [Abstract][Full Text] [Related]
3. Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.
Nielsen DA; Walker R; Graham DP; Nielsen EM; Hamon SC; Hillhouse M; Shmueli-Blumberg D; Lawson WB; Shores-Wilson K; Settles-Reaves BD; Rotrosen J; Trivedi MH; Saxon AJ; Ling W; Kosten TR
Eur J Clin Pharmacol; 2022 Jun; 78(6):965-973. PubMed ID: 35218405
[TBL] [Abstract][Full Text] [Related]
4. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
[TBL] [Abstract][Full Text] [Related]
6. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
[TBL] [Abstract][Full Text] [Related]
7. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
[TBL] [Abstract][Full Text] [Related]
8. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
[TBL] [Abstract][Full Text] [Related]
10. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
13. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
Roache JD; Pavlicova M; Campbell A; Choo TH; Peavy M; Kermack AS; Nunes EV; Rotrosen J
Alcohol Clin Exp Res; 2021 Dec; 45(12):2569-2578. PubMed ID: 34698397
[TBL] [Abstract][Full Text] [Related]
14. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
Randesi M; Rotrosen J; Nunes EV; Lee JD; Novo P; Levran O; Ott J; Pavlicova M; Scodes J; Kreek MJ
Am J Drug Alcohol Abuse; 2020 Nov; 46(6):761-768. PubMed ID: 32851876
[No Abstract] [Full Text] [Related]
15. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
Tsui JI; Campbell ANC; Pavlicova M; Choo TH; Lee JD; Cook RR; Shulman M; Nunes EV; Rotrosen J
Drug Alcohol Depend; 2022 Jul; 236():109469. PubMed ID: 35605529
[TBL] [Abstract][Full Text] [Related]
17. Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Opheim A; Benth JŠ; Solli KK; Kloster PS; Fadnes LT; Kunøe N; Gaulen Z; Tanum L
Contemp Clin Trials; 2023 Dec; 135():107360. PubMed ID: 37865138
[TBL] [Abstract][Full Text] [Related]
18. Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.
Haeny AM; Montgomery L; Burlew AK; Campbell ANC; Scodes J; Pavlicova M; Rotrosen J; Nunes E
Addict Behav; 2020 Nov; 110():106514. PubMed ID: 32619868
[TBL] [Abstract][Full Text] [Related]
19. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Latif ZE; Šaltyte Benth J; Solli KK; Opheim A; Kunoe N; Krajci P; Sharma-Haase K; Tanum L
JAMA Psychiatry; 2019 Feb; 76(2):127-134. PubMed ID: 30566177
[TBL] [Abstract][Full Text] [Related]
20. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
